Touyun Biotech Group Limited (HKG:1332)
Hong Kong · Delayed Price · Currency is HKD 0.1580
-0.0010 (-0.63%)
Sep 4, 2026, 3:59 PM HKT
Touyun Biotech Group Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 70.76 | 71.95 | 91.93 | 198.03 | 323.33 | 292.39 |
Other Revenue | 0.16 | -4.98 | 7.67 | 0.61 | -7.51 | -8.88 |
| 70.92 | 66.97 | 99.6 | 198.64 | 315.83 | 283.51 | |
Revenue Growth | -50.62% | -32.76% | -49.86% | -37.10% | 11.40% | 37.10% |
Cost of Revenue | 55.23 | 50.75 | 60.9 | 144.77 | 195.71 | 176.45 |
Gross Profit | 15.69 | 16.22 | 38.7 | 53.88 | 120.12 | 107.05 |
Selling, General & Admin | 66.99 | 76.62 | 72.87 | 141.71 | 154.68 | 144.74 |
Operating Expenses | 65.3 | 76.36 | 75.21 | 144.03 | 162.58 | 145.2 |
Operating Income | -49.61 | -60.14 | -36.51 | -90.15 | -42.47 | -38.15 |
Interest Expense | -32.1 | -21.18 | -9.69 | -7.43 | -21.65 | -17.14 |
Interest & Investment Income | 0.01 | 0.02 | 0.07 | 0.14 | 0.1 | 0.17 |
Currency Exchange Gain (Loss) | -0.93 | -0.68 | 0.69 | 0.89 | 2.76 | -1.25 |
Other Non Operating Income (Expenses) | 3.72 | 4.51 | 4.24 | 4.3 | 5.16 | 10.35 |
EBT Excluding Unusual Items | -78.9 | -77.48 | -41.2 | -92.26 | -56.1 | -46.02 |
Gain (Loss) on Sale of Investments | 405.36 | 129.22 | -38.12 | -99.54 | -140.27 | -54.05 |
Gain (Loss) on Sale of Assets | 1.72 | 1.72 | -0 | -2.05 | -2.82 | -22.91 |
Asset Writedown | -5.5 | -5.5 | - | -78.75 | - | - |
Other Unusual Items | -0.49 | -0.38 | 0.17 | - | - | - |
Pretax Income | 322.19 | 47.57 | -79.16 | -272.59 | -199.18 | -122.97 |
Income Tax Expense | 0.02 | 0.01 | -0.33 | -0.02 | 3.47 | 0.97 |
Earnings From Continuing Operations | 322.17 | 47.56 | -78.83 | -272.57 | -202.66 | -123.94 |
Earnings From Discontinued Operations | 21.87 | 13.74 | -9.21 | - | - | - |
Net Income to Company | 344.04 | 61.3 | -88.04 | -272.57 | -202.66 | -123.94 |
Minority Interest in Earnings | -130.64 | -34.5 | -0.07 | 3.63 | 4.59 | 50.99 |
Net Income | 213.4 | 26.8 | -88.11 | -268.94 | -198.07 | -72.95 |
Net Income to Common | 213.4 | 26.8 | -88.11 | -268.94 | -198.07 | -72.95 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 2,806 | 2,806 | 2,806 | 2,806 | 2,806 | 2,795 |
Shares Outstanding (Diluted) | 2,808 | 2,808 | 2,806 | 2,806 | 2,806 | 2,795 |
Shares Change | 0.09% | 0.09% | - | - | 0.39% | 4.58% |
EPS (Basic) | 0.08 | 0.01 | -0.03 | -0.10 | -0.07 | -0.03 |
EPS (Diluted) | 0.08 | 0.01 | -0.03 | -0.10 | -0.07 | -0.03 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -30.8 | -53.64 | -14.95 | -39.3 | -217.32 |
Free Cash Flow Per Share | - | -0.01 | -0.02 | -0.01 | -0.01 | -0.08 |
Gross Margin | 22.12% | 24.22% | 38.86% | 27.12% | 38.03% | 37.76% |
Operating Margin | -69.95% | -89.81% | -36.66% | -45.38% | -13.45% | -13.46% |
Profit Margin | 300.92% | 40.02% | -88.46% | -135.39% | -62.71% | -25.73% |
Free Cash Flow Margin | - | -45.99% | -53.86% | -7.53% | -12.44% | -76.66% |
EBITDA | -31.65 | -47.87 | -23.21 | -71.41 | -30.25 | -34.44 |
EBITDA Margin | -44.63% | -71.47% | -23.30% | -35.95% | -9.58% | -12.15% |
D&A For EBITDA | 17.96 | 12.28 | 13.31 | 18.74 | 12.22 | 3.71 |
EBIT | -49.61 | -60.14 | -36.51 | -90.15 | -42.47 | -38.15 |
EBIT Margin | -69.95% | -89.81% | -36.66% | -45.38% | -13.45% | -13.46% |
Effective Tax Rate | 0.01% | 0.02% | - | - | - | - |